The global antibodies contract manufacturing market size was estimated at USD 17.79 billion in 2024 and is projected to reach USD 31.76 billion by 2030, growing at a CAGR of 10.1% from 2025 to 2030. This strong growth is primarily driven by the increasing focus of biopharmaceutical and biotechnology companies on the development and large-scale manufacturing of antibody-based therapeutics. Antibody therapies have demonstrated high efficacy in the treatment of a wide range of diseases, including various cancers, rheumatoid arthritis, and other chronic and immune-related disorders. As the global burden of chronic diseases continues to rise, demand for therapeutic antibodies is increasing across healthcare systems worldwide. To meet this growing demand, pharmaceutical companies are increasingly outsourcing manufacturing activities to contract manufacturing organizations (CMOs), thereby expanding the antibody contract manufacturing market and enabling faster scale-up of production.

Biopharmaceutical manufacturing is widely recognized as one of the fastest-growing sectors within the pharmaceutical industry, with significant long-term revenue potential. Many healthcare and industry stakeholders consider this sector to be among the top 10 revenue-generating segments in the coming years due to the increasing adoption of biologics and personalized medicines. Market players are continuously investing in capacity expansion, process optimization, and advanced manufacturing technologies to address the rising demand for bio-based pharmaceuticals. This trend is expected to result in a growing number of CMOs and CDMOs focusing specifically on biopharmaceutical production. For example, in February 2024, Catalent’s acquisition by Novo Holdings and the subsequent expansion of its European manufacturing facilities strengthened its antibody production capabilities, particularly for small molecules and biologics used in advanced therapeutic applications. This expansion supports Catalent’s broader strategy to enhance its therapeutic portfolio, including cell and gene therapies.

The healthy growth of the biopharmaceutical sector has also led to the development of an extensive and diverse product pipeline, particularly in antibody-based drugs. An increasing number of monoclonal and polyclonal antibodies are advancing through preclinical and clinical development stages, creating sustained demand for specialized manufacturing expertise. Contract manufacturers offer biopharmaceutical companies access to advanced infrastructure, regulatory compliance capabilities, and scalable production platforms without the need for substantial capital investment. As a result, outsourcing antibody manufacturing has become a strategic approach for companies aiming to accelerate time-to-market while managing costs and operational risks. This growing reliance on external manufacturing partners continues to strengthen the antibodies contract manufacturing market.

Key Market Trends & Insights:

• North America dominated the global antibody contract manufacturing market in 2024, accounting for approximately 34.17% of total revenue. This dominance is attributed to the high concentration of biopharmaceutical companies, extensive biologics manufacturing activity, and the presence of a large number of established CDMO and CMO facilities across the region.
• The Asia Pacific antibody contract manufacturing market is expected to be the fastest-growing during the forecast period. This rapid growth is supported by favorable regulatory reforms, improving healthcare and manufacturing infrastructure, lower production costs, and the availability of a large pool of potential study subjects, making the region increasingly attractive for biopharmaceutical manufacturing and clinical research.
• Based on product, monoclonal antibodies dominated the market with a revenue share of 76.42% in 2024, reflecting their widespread use in oncology, autoimmune, and inflammatory disease treatments. The polyclonal antibodies segment is anticipated to grow significantly over the forecast period, supported by expanding applications and ongoing research initiatives.
• Based on source, the mammalian source segment held the largest market share of 57.52% in 2024, owing to its ability to produce complex antibodies with appropriate post-translational modifications. Meanwhile, the microbial source segment is expected to grow substantially during the forecast period, as microbial systems such as Escherichia coli and yeast provide efficient, scalable, and cost-effective platforms for antibody production.
• Based on end use, the biopharmaceutical companies segment accounted for the largest share of over 66.49% in 2024 and is also projected to be the fastest-growing segment throughout the forecast period. This growth is driven by increasing outsourcing of antibody manufacturing activities by biopharmaceutical companies seeking to focus on core research and development while leveraging external manufacturing expertise.

Order a free sample PDF of the Antibodies Contract Manufacturing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 17.79 Billion
• 2030 Projected Market Size: USD 31.76 Billion
• CAGR (2025-2030): 10.1%
• North America: Largest market in 2024

Key Players

• Lonza
• Samsung Biologics
• WuXi Biologics.
• Charles River Laboratories
• FUJIFILM Holdings Corporation
• Boehringer Ingelheim Biopharmaceuticals GmbH
• AGC Biologics
• Cytovance Biologics, Inc.
• EMERGENT
• Thermo Fisher Scientific
• Labcorp Drug Development
• Catalent, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the antibodies contract manufacturing market is poised for strong growth, driven by the increasing adoption of antibody-based therapeutics for the treatment of chronic and life-threatening diseases. The expanding biopharmaceutical pipeline and growing preference for outsourcing manufacturing activities are encouraging companies to partner with specialized CMOs and CDMOs. Continued investments in manufacturing capacity, process optimization, and advanced production technologies further support market expansion. While North America remains the dominant region, Asia Pacific is emerging as a high-growth market due to improving infrastructure and regulatory support. Overall, these factors collectively position the market for sustained growth throughout the forecast period.